Par Drugs and Chemicals Limited (PAR.NS)
ValueMarkers Composite Index
75% below intrinsic value ($4)
Par Drugs and Chemicals Limited (PAR.NS) — VMCI valuation read
PAR.NS screens at VMCI 66/100, a 16-point gap above the Healthcare sector median (50). For a mid-cap Par Drugs and Chemicals Limited share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.
PAR.NS has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.
**Investor frame.** Value: PAR.NS trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp, the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 1.8x is the rate-sensitivity line to watch, which sets the rate-cycle exposure for Par Drugs and Chemicals Limited.
PAR.NS fell 1.6% over the trailing 7 days, with a -13.6% read on a 30-day basis.
Par Drugs and Chemicals Limited develops, produces, and sells active pharma ingredients and fine chemicals in India. It offers magnesium salts, dried aluminum hydroxide gel, sodium aluminum silicate, precipitated silica, magnesium silicate, colloidal silicon dioxide, sucralfate USP, and amorphous and blended products. The company also exports its products. Par Drugs and Chemicals Limited was founded in 1982 and is based in Vadodara, India.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.